MDT-AP-1177
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 12
- os_event
- false
- age_years
- 1
- sex
- M
- new_clusters
- S3
- umap1_2d
- -0.871846469
- umap2_2d
- -7.41614717
- umap1_3d
- -3.257575954
- umap2_3d
- -2.983512998
- umap3_3d
- 5.853697063
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- ANGIOGENESIS+0.480
- INTERFERON_ALPHA_RESPONSE+0.480
- ALLOGRAFT_REJECTION+0.450
- INFLAMMATORY_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.430
- COMPLEMENT+0.390
- IL6_JAK_STAT3_SIGNALING+0.380
- COAGULATION+0.370
- APICAL_SURFACE+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.380
- MTORC1_SIGNALING-0.360
- OXIDATIVE_PHOSPHORYLATION-0.360
- DNA_REPAIR-0.330
- MYC_TARGETS_V1-0.320
- PROTEIN_SECRETION-0.320
- E2F_TARGETS-0.250
- G2M_CHECKPOINT-0.220
- PEROXISOME-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.920 |
| 2 | ERR2208918 | — | — | 0.919 |
| 3 | MNG1293 | — | — | 0.910 |
| 4 | BS_FQX1PRAJ | Neurofibroma | — | 0.909 |
| 5 | sclcA055A_S52.txt | — | cohortMD2 | 0.908 |
| 6 | TCGA-44-7672-01A-11R-2066-07 | — | cohortA1 | 0.907 |
| 7 | 20120155.TNBC | — | D | 0.905 |
| 8 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.905 |
| 9 | SRR12202441 | — | — | 0.903 |
| 10 | SRR2771286 | — | — | 0.903 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.320 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |